18,003 recalls, newest first
Marketed without an approved NDA/ANDA - New Life Nutritional Center is recalling SUPER FAT BURNER, MAXI GOLD WEIGHT LOSS PILL and Esmeralda products marketed as Dietary Supplements due to the presence of undeclared and unapproved drugs.
Marketed without an approved NDA/ANDA - New Life Nutritional Center is recalling SUPER FAT BURNER, MAXI GOLD WEIGHT LOSS PILL and Esmeralda products marketed as Dietary Supplements due to the presence of undeclared and unapproved drugs.
CGMP Deviations; laboratory testing was not followed in accordance with GMP requirements
Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.
Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.
Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.
Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.
Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.
Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.
Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.
Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.
Chemical Contamination: Product were manufactured with active pharmaceutical ingredient (API) batches contaminated with residual materials and solvents.
CGMP Deviations; laboratory testing was not followed in accordance with GMP requirements.
CGMP Deviations; laboratory testing was not followed in accordance with GMP requirements
CGMP Deviations; laboratory testing was not followed in accordance with GMP requirements
Non-sterility: due to a failed sterility test
Failed Impurities/Degradation Specifications: Out of Specification for an impurity at the 18 month stability time point.
Failed Dissolution Specifications: Stability results found the product did not meet the drug release dissolution specifications.
Failed Dissolution Specifications: Stability results found the product did not meet the drug release dissolution specifications.
Presence of Foreign Tablets/Capsules: Recall is due to a pharmacist complaint of a "foreign material", identified as Metoprolol Tartrate Tablet USP 50 mg, found co-mingled in a bottle of Ranitidine Tablets USP 150 mg.
Presence of Particulate Matter
Labeling: Incorrect Expiration Date; Expiration date is earlier than listed on vial.
Labeling: Incorrect Expiration Date; Expiration date is earlier than listed on vial.
Labeling: Incorrect Expiration Date; Expiration date is earlier than listed on vial.
Presence of Particulate Matter; Particulates identified as stainless steel and barium sulfate.